PROTEINA has developed the first-in-class protein-protein interaction (PPI) analysis platform using proprietary 'single-molecule co-immunoprecipitation' technology. Our platform enables quantitative PPI measurements at the single-molecule level, delivering analyses with unparalleled accuracy and speed. PROTEINA has accumulated extensive know-how in developing assays measuring targeted PPIs as well as the analytic capability to model the efficacy of a drug based on its PPI metrics. Our mission is to revolutionize protein analysis; developing effective, new approaches to diagnosing diseases and discovering new drug candidates using our novel technology. For more information regarding PROTEINA, please visit us at www.proteina.co.kr.